September 19, 2017 / 11:42 AM / 3 months ago

BRIEF-Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

Sept 19 (Reuters) - Cytokinetics Inc

* Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

* Cytokinetics - ‍pharmacokinetics, pharmacodynamics, safety, tolerability data from trial were consistent with previously reported results from COSMIC-HF​

* Cytokinetics Inc - ‍ coincident with patient dosing in galactic-hf, Amgen will make a $10 million milestone payment to Cytokinetics​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below